Cue Biopharma Inc Kurs/ Buchwert
Was ist das Kurs/ Buchwert von Cue Biopharma Inc?
Kurs/ Buchwert von Cue Biopharma Inc ist 3.42
Was ist die Definition von Kurs/ Buchwert?
Kurs-Buchwert-Verhältnis repräsentiert das Verhältnis zwischen dem Aktienwert eines Unternehmens und dem Buchwert pro Aktie.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Kurs/ Buchwert von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cue Biopharma Inc
Was macht Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Unternehmen mit kurs/ buchwert ähnlich Cue Biopharma Inc
- Ajinomoto Co hat Kurs/ Buchwert von 3.42
- Sampo Oyj hat Kurs/ Buchwert von 3.42
- Home Bistro Inc hat Kurs/ Buchwert von 3.42
- ClearBridge MLP and Midstream Fund Inc hat Kurs/ Buchwert von 3.42
- TE Connectivity hat Kurs/ Buchwert von 3.42
- Palla Pharma hat Kurs/ Buchwert von 3.42
- Cue Biopharma Inc hat Kurs/ Buchwert von 3.42
- Hao Bai International (Cayman) hat Kurs/ Buchwert von 3.42
- Trisura hat Kurs/ Buchwert von 3.43
- Rashtriya Chemicals and Fertilizers hat Kurs/ Buchwert von 3.43
- Usio hat Kurs/ Buchwert von 3.43
- United Utilities Plc hat Kurs/ Buchwert von 3.43
- Element 25 hat Kurs/ Buchwert von 3.43